SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

CLINICAL RESEARCH AND ADR MONITORING

Mr. Sidheshwar Shewale, Mr. Jagdish Shewale,
Mr. Sachin Dighole, Miss. Mansi Kaushik, Dr. Sunil Jaybhay.
Institute of Pharmacy, (NKSPT) Pathrikar Campus, Badnapur, Jalna. 431202

ABSTRACT

Clinical research is a branch of healthcare science that involves the systematic investigation of human health and disease to improve diagnostic, preventive, and therapeutic practices.

It encompasses various study designs, including observational studies, clinical trials, and translational research, aimed at enhancing patient care and advancing medical knowledge.

Clinical research is fundamental in evaluating the safety and efficacy of new drugs, medical devices, and treatment protocols, ultimately influencing regulatory approvals and healthcare guidelines.

The field faces challenges like recruitment, retention of participants, and balancing scientific rigor with practical application.

Advances in digital health, data analytics, and personalized medicine are shaping the future of clinical research, fostering innovation and more patient-centered approaches.

The ultimate goal is to bridge the gap between laboratory discoveries and real-world applications, improving healthcare outcomes globally.

KEY WORDS: *Study Design , Study Protocol , Ethical Considerations , Study Population , Interventions and Controls, Outcome Measures , Data Collection and Management , Statistical Analysis .*

INTRODUCTION

Clinical research is a branch of medical science that involves the study of human participants to evaluate the safety, efficacy, and effectiveness of medical interventions, including drugs, devices, treatments, and diagnostic tools.
It is essential in the advancement of medicine and plays a critical role in bringing new therapies to patients.

- Clinical research provides evidence for new and improved medical practices, such as treatment modalities, management approaches, diagnoses, and prevention strategies
- Understanding how to develop a study question and choose study designs is critical to fully grasp what clinical research entails and why it is important
- Clinical studies can be broadly classified into two design categories: observational, in which researchers only collect available data, and experimental, in which investigators control the exposure
- Every type of study serves a unique purpose, but only randomized controlled trials can determine causality between independent and dependent variables
- A component of medical and health research intended to produce knowledge essential for understanding human disease, preventing and treating illness, and promoting health. Clinical research embraces a continuum of studies involving interaction with patients, diagnostic.

Clinical Trial's

Clinical trials are research studies conducted to evaluate the safety, efficacy, and effectiveness of medical interventions, including drugs, medical devices, therapies, or diagnostic tools.

They are essential for advancing medical knowledge and ensuring that new treatments are both safe and beneficial for patient.
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Clinical trials generate data on dosage, safety and efficacy.
Clinical trials are systematic research studies conducted to evaluate the safety, efficacy, and effectiveness of medical interventions such as drugs, vaccines, medical devices, and treatment protocols.

The primary goal of clinical trials is to improve patient care by testing innovative approaches to preventing, diagnosing, and treating diseases

Purposes of Clinical Trial's

1) Assessing Safety
2) Evaluating Efficacy
3) Developing Better Treatments
4) Preventing Diseases
5) Improving Quality of Life
6) Advancing Personalized Medicine

Goal's Clinical Trial's

- **Aimed at improving medical care, advancing scientific knowledge, and ensuring patient safety.**

1. Evaluating Safety
2. Supporting Regulatory Approval
3. Advancing Medical Knowledge
4. Promoting Personalized Medicine
5. Improving Patient Outcomes
6. Exploring Preventive Measures

2. Phases of Clinical Trial's

A. Preclinical Phase (Before Human Testing)
B. Phase I: First-in-Human Trials
C. Phase II: Efficacy and Safety Trials
D. Phase III: Large-Scale Trials
E. Phase IV: Post-Marketing Surveillance




Fig. 3 Phases of Clinical Trial's

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

A. Preclinical Phase (Before Human Testing)

The preclinical phase is the first stage of research conducted before new drugs, treatments, or medical interventions are tested on humans. **It aims to assess the potential efficacy and safety of a treatment through laboratory and animal studies.**
This phase is critical for identifying promising candidates and ensuring they meet safety standards before advancing to human clinical trials.

Objective

1. **Discovery and Target Identification**
2. **Lead optimization**
3. **In Vitro Studies (Cell-Based Studies)**
4. **In Vivo Studies (Animal Testing)**
5. **Formulation Development**

B. Phase I: First-in-Human Trials

Phase 1 clinical research is the first stage of human clinical trials in drug development.
Its main objective is to evaluate the safety, dosage, and pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted by the body) of a new drug or treatment.
It is typically conducted after preclinical studies, which involve laboratory and animal testing, have shown initial promise regarding the drug's safety and efficacy.

Participants: Phase 1 trials typically involve a small number of healthy volunteers (20-100) participant.

Objectives

- **Safety**
  The primary goal is to assess the safety of the drug, identify any potential side effects or adverse reactions, and determine if the drug is safe enough to proceed to the next phase.
- **Dose-Escalation**
  Researchers begin by administering a very low dose of the drug to a few participants and gradually increase the dose in subsequent groups to determine the maximum tolerable dose (MTD) and the dose at which side effects become intolerable.

Study Design

- **Single Ascending Dose (SAD)**:
  In this design, participants receive a single dose of the drug, and the dose is gradually increased in different groups of participants until the MTD is found.
- **Multiple Ascending Dose (MAD)**:
  This design involves giving participants multiple doses of the drug over several days or weeks, again with increasing doses to assess the effects of prolonged exposure.

Goals of Phase 1

- **Safety Profile**
  The most important goal is to assess the safety of the drug and identify any potential risks or harmful side effects.
- **Dosage**
  Establish the appropriate dosage range for further testing in Phase 2 clinical trials.
- **Pharmacokinetics and Pharmacodynamics**
  Collect initial data on how the drug works in the body.

C. Phase II: Efficacy and Safety Trials

A Phase 2 clinical trial is a critical stage in the drug development process, coming after Phase 1 trials and before Phase 3 trials.
The primary focus of Phase 2 is to evaluate the effectiveness of a drug or treatment, continue to assess its safety, and further refine its optimal dosage.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Objective

1. Effectiveness (Efficacy)

The main goal of Phase 2 is to assess whether the drug or treatment works as intended in patients who have the condition or disease the drug is meant to treat.

2. Safety (Adverse Effects and Toxicity):

Although Phase 1 trials primarily focus on safety, Phase 2 continues to monitor for any potential side effects or adverse reactions.

3. Dose Range

Phase 2 studies explore the optimal dose or dosage range that balances effectiveness and safety.

Duration of Phase 2 Trials

Duration: Typically lasts between 6 months and 2 years, depending on the disease being studied, the drug's mechanism of action, and the desired endpoints.

Moving from Phase 2 to Phase 3

If the Phase 2 trial shows that the drug is both effective and safe at a reasonable dose, it moves on to Phase 3

D. Phase III: Large-Scale Trials

Phase 3 clinical trials are a critical stage in the development of new drugs, medical devices, or treatments.
These trials are designed to confirm the effectiveness and safety of an intervention in a larger, more diverse population, and they form the basis for regulatory approval by agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Main Objectives

1. Confirm the efficacy of the intervention
2. Compare the intervention to existing treatments
3. Assess optimal dosing and administration

- **Trial Design**

Randomization: Participants are randomly assigned to different treatment arms (e.g., new drug vs. placebo or standard treatment).

Control group: A group of participants that receives either a placebo (an inactive treatment) or the standard of care for comparison.

- **Duration**

Phase 3 trials can last from several months to several years, depending on the condition being studied and the treatment being tested.

Challenges in Phase 3 Trials

Recruitment:

Finding enough eligible participants can be a challenge, especially for rare diseases or when strict inclusion/exclusion criteria are applied.

Ethical Issues:

There may be ethical concerns, especially when studying potentially life-saving treatments.

E. Phase IV: Post-Marketing Surveillance

- Post-Phase 3: Post-Marketing Surveillance

This helps detect any long-term or rare side effects that were not evident during Phase 3 trials.
Phase 4 clinical trials, also known as post-marketing surveillance trials, occur after a drug or treatment has been approved by regulatory authorities (like the FDA) and is available on the market.

These trials are designed to monitor the long-term safety, effectiveness, and overall impact of the drug or treatment in a broader population.

Phase 4 trials can also assess the drug's performance in various subgroups of patients and in realworld conditions, which may differ from the controlled environment of earlier phases.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Key Word's : - Long-Term Safety Monitoring , Effectiveness in the General Population , Comparative Effectiveness , New Uses , Risk Management.

Trials

- **Registry Studies:**
  Large observational studies where data is collected from patients over time to monitor drug effects in a real-world setting.
- **Post-Approval Safety Studies**:
  Studies specifically designed to gather more information about the safety of a drug after it has been widely distributed.
- **Observational Studies**:
  Researchers observe how patients are treated in normal clinical practice without assigning specific interventions.
- **Patient Surveys and Reporting**:
  Patients or healthcare providers may be asked to report side effects, which contribute to the overall safety data.

Challenges

Data Collection

Because Phase 4 trials often involve larger, more diverse populations, data collection can be more complex and harder to control.

Cost

Post-marketing surveillance can be expensive, as it may require long-term follow-up with large numbers of patients.

Compliance

Patients may not always follow protocols as strictly as in earlier trial phases, which can make it harder to interpret results.

In short, Phase 4 trials are a critical part of the drug approval process, offering insights into a medication's safety and effectiveness once it's widely used in the general population.

Ethical Consideration

Ethical considerations in clinical research are critical to ensuring the rights, safety, and well-being of participants, as well as maintaining the integrity and trustworthiness of the scientific process.

Clinical research typically involves human subjects, and it is therefore necessary to apply ethical principles that safeguard their dignity, autonomy, and rights while contributing to scientific knowledge.
Clinical research plays a critical role in health care delivery.
It's through clinical research that scientists develop new treatments, cures and preventive measures that help mediate the spread of disease.

Key Elements of Ethical Consideration

1. Informed Consent

Participants must voluntarily agree to participate in research after being fully informed about the study's nature, risks, benefits, and alternatives.

2. Risk and Benefit Assessment

The ethical principle of beneficence dictates that research should aim to benefit participants or society, while minimizing harm.

Minimal Risk:

Risks should be as low as possible, particularly in vulnerable populations (e.g., children, pregnant women, or individuals with cognitive impairments).

Maximizing Benefit:

Efforts should be made to ensure that the study has the potential for meaningful scientific or therapeutic benefits.

Monitoring Risks:

An independent Data Safety Monitoring Board (DSMB) or similar oversight mechanisms may be employed to monitor the safety of participants throughout the study.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

4. **Confidentiality and Privacy**

Respecting the privacy and confidentiality of participants is essential in clinical research. Researchers are obligated to protect sensitive information, including medical history, personal details, and any data collected during the study.

Data Protection:

Confidentiality must be maintained by anonymizing or de-identifying data whenever possible, and using secure systems for data storage and transmission.

Legal and Ethical Guidelines:

Researchers must comply with data protection laws (e.g., GDPR in Europe, HIPAA in the United States) to ensure participants' rights are respected.

❖ **ADR Monitoring & Reporting**

Adverse Drug Reactions (ADRs) refer to any harmful, unintended, and undesirable effects that occur when a drug is administered at normal therapeutic doses.

These reactions can range from mild side effects to life-threatening conditions, and their monitoring is crucial to ensuring the safety and efficacy of medications.

In healthcare, **ADR monitoring and reporting** play a critical role in identifying, evaluating, and mitigating the risks associated with drug use.

This process involves systematic data collection from various sources, including healthcare providers, patients, clinical trials, and post-marketing surveillance programs. Advanced tools like **electronic health records (EHRs**), data mining algorithms, and artificial intelligence have revolutionized ADR monitoring, enabling rapid detection and analysis of drug-related risks.

ADR monitoring is essential for regulatory authorities, pharmaceutical companies, and healthcare institutions to make evidence-based decisions regarding drug approvals, label modifications, or withdrawals.
Public awareness and active participation in ADR reporting further strengthen pharmacovigilance efforts.

ADR Monitoring

ADR monitoring involves the ongoing surveillance of the effects of medications in patients, specifically focusing on detecting adverse reactions that may not have been identified in clinical trials.

ADR Reporting

ADR reporting refers to the process of documenting and communicating suspected ADRs to relevant regulatory bodies, healthcare authorities, or pharmaceutical companies**.**

➢ **Fig. 4 Chart For ADR (Adverse Drug Reaction) Reporting Drug Lisinopril, Metformin, Aspirin, Amoxicillin.**

Date of Reported	2024/11/01	2024/11/03	2024/11/05	2024/11/07
Patient ID	001	002	003	004
Age/Sex	58/M	45/F	70/M	21/F
Drug(S) Involved	Lisnopril	Metformin	Aspirin	Amoxicillin
Dosage & Administration	10 mg saily	500 mg dealy	75 mg dealy	250 mg TID
Adverse Reaction	Dizziness, Cough	Nausea, Vomiting	Gastrointestinal Bleading	Skin Rash
Severty	Moderate	Mild	Severe	Mild
Outcome	Recovered	Ongoing	Hospitalized	Recovered
Date of Onset	2024/10/30	2024/11/02	2024/11/04	2024/11/06

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Date of Resolution	2024/11/05	N/A	N/A	2024/11/08
Reporter (Phisician/Pharmacist/Patient)	Dr. Mansi (gynecologist)	Sidheshwar (Pharmacist)	Dr. Gautam	Nurse
Type of ADR	Type A (columnon)	Type B (uncommon)	Type C (Dose related)	Type B (Uncommon)
Reporting Source	Hospital	Patient	Physician	ER Department
Follow-up-Action taken	Dose Adjustment, Monitoring.	Symptom Management.	Immediate Discontinuation, Blood Transfusion.	Discontinued Drug, Antihistamine Given.

Purposes of ADR Monitoring & Reporting

1. Safety Assessment

- **Identifying harmful effects**
  ADR monitoring helps detect and assess the harmful effects of drugs that may not have been identified during clinical trials due to limited sample sizes or trial conditions.
- **Risk mitigation:**
  By identifying ADRs, healthcare professionals can take steps to mitigate risks, such as adjusting dosage, changing medications, or issuing safety warnings.

2. Regulatory Compliance

Pharmacovigilance requirements:
Regulatory bodies like the FDA, EMA, and WHO require ongoing ADR reporting and monitoring as part of pharmacovigilance to ensure that drug products remain safe for public use.

- **Labeling updates:**
  ADR data can lead to updates in drug labeling, including new warnings or contraindications, helping to guide healthcare providers in making safer prescribing decisions.

3. Post-market Surveillance

Long-term safety monitoring:
ADR monitoring continues after a drug is approved and released to the market. This helps identify rare, long-term, or delayed side effects that may not have been evident in pre-market clinical trials.

- **Population diversity:**
  In the real-world population, patients often have diverse conditions, comorbidities, and genetic differences that may result in ADRs not seen in controlled clinical trials.

Important's of ADR Reporting & Monitoring

1. Ensures Patient Safety

- **Identification of Risks:**
  Monitoring ADRs helps identify potential risks associated with a drug. By collecting data from realworld use, healthcare professionals can detect rare, unexpected, or severe reactions that might not have been identified during clinical trials.
- **Preventing Harm**
  Early detection of ADRs can lead to appropriate changes in treatment protocols, dosage adjustments, or even the removal of unsafe drugs from the market, ultimately preventing further harm to patients.

2. Improves Drug Safety Profile

Data for Risk Assessment:
Continuous ADR reporting allows healthcare providers, regulators, and pharmaceutical companies to assess the risk-benefit ratio of medications in diverse populations.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

This can lead to better labeling, warnings, or contraindications for specific groups of patients (e.g., children, pregnant women, elderly).

- **Labeling Updates**:
  Information from ADR reporting systems can prompt revisions in drug labels to reflect known side effects, ensuring that patients and clinicians are better informed.

3. Enhances Pharmacovigilance

Global Collaboration:

ADR monitoring contributes to pharmacovigilance, the science of detecting, assessing, and understanding drug-related risks. International collaboration through databases like VigiBase ensures a global perspective on drug safety.

4. Enhances Pharmaceutical Development

Informs Drug Development:

ADR data can also be used by pharmaceutical companies to improve the design of future drugs, refine formulations, or develop new drugs with fewer side effects.

Companies may use ADR information to enhance the clinical trial process for subsequent drug candidates.

- **Continuous Feedback Loop:**
  By analyzing ADRs, pharmaceutical companies gain valuable feedback about their drugs' performance in the real world, which can influence both marketing strategies and product improvements

➢ **Who Reports ADRs**

A Who Report in the context of ADR (Adverse Drug Reaction) typically refers to a report issued by the **World Health Organization (WHO)** on adverse drug reactions. The WHO maintains a global pharmacovigilance system to monitor and report adverse drug reactions, particularly through the WHO Collaborating Centre for International Drug Monitoring based in **Uppsala, Sweden**. This center operates the **Uppsala Monitoring Centre (UMC),** which collects and analyzes reports of adverse drug reactions from healthcare professionals, patients, and regulatory agencies worldwide.

➢ **Regulatory Frameworks**

Global Pharmacovigilance: International organizations, including the WHO's **Uppsala Monitoring Centre (UMC),** collect and analyze ADR data from all over the world.

The goal is to detect safety signals, identify risks, and provide guidance on the safe use of medicines globally.

National Regulatory Agencies

Countries have their own pharmacovigilance systems to manage ADR data. In the U.S., the FDA operates the MedWatch system, while the EMA in Europe coordinates reporting through the EudraVigilance database.

➢ **Reporting Systems**

Spontaneous Reporting Systems:

These systems allow healthcare professionals or patients to voluntarily report ADRs. In the U.S., MedWatch is the primary system for spontaneous reporting.

In Europe, similar reporting is done through national databases linked to EudraVigilance.

Electronic Reporting:

Many countries have introduced electronic methods for reporting ADRs, which have streamlined the process, making it easier for healthcare providers and patients to submit ADR information.

Challenges in ADR Monitoring and Reporting:

Underreporting:

A significant challenge is that many ADRs go unreported, especially in cases where the reaction is mild or not immediately recognized as related to a drug.

- **Incomplete Data:**
  The data gathered may be insufficient for a full understanding of the ADR, which can delay decisionmaking.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

- **Complexity in Causality Assessment:**
  Determining whether a drug is the cause of an adverse event can be difficult, especially when other factors (e.g., co-existing diseases, drug interactions) are involved.

Benefits of ADR Monitoring and Reporting:

Improved Drug Safety:
Ongoing ADR surveillance helps identify risks associated with medications, leading to better understanding of their safety profiles.

- **Risk Minimization**:
  With early detection of ADRs, manufacturers and healthcare providers can take proactive measures, such as adjusting dosage recommendations or issuing warnings to patients.

CONCLUSION

Clinical research plays a pivotal role in advancing medical knowledge and improving patient outcomes.
By investigating the safety and efficacy of new interventions, clinical trials provide valuable insights that guide treatment decisions and enhance the quality of care.

Furthermore, research findings inform evidence-based guidelines, empowering healthcare providers to deliver personalized and effective therapies tailored to individual patient needs.

Clinical data management is an essential aspect of clinical research, ensuring that the data collected is organized and accessible for analysis and reporting.

- Conduct clinical trials to compare the effectiveness of different treatment options that are already approved for clinical use,
- Combine novel therapies developed by different sponsors,
- Develop therapies for rare diseases,
- Determine optimal duration and dose of treatment with drugs in clinical use,
- Test multimodality therapies, such as radiation therapy, surgery, or devices in combination with drugs,

Clinical research serves as the foundation of evidence-based medicine, driving advancements in disease prevention, diagnosis, treatment, and patient care. The outcomes of clinical research contribute to the development of safer and more effective therapeutic interventions, while also shaping clinical guidelines and healthcare policies.
Despite its transformative potential, clinical research faces challenges such as ethical considerations, patient recruitment, and resource constraints. Addressing these issues requires collaboration among stakeholders, adherence to ethical principles, and innovative approaches to study design and execution.

In conclusion, clinical research is indispensable for improving health outcomes and enhancing the quality of life.
ADR monitoring and reporting are essential components of the pharmacovigilance framework, ensuring that drugs are used safely and effectively.
Ongoing improvements in reporting systems, increased awareness among healthcare professionals, and robust regulatory oversight will continue to enhance patient safety and the overall benefit-risk profile of medications.

Adverse Drug Reaction (ADR) monitoring and reporting are indispensable components of pharmacovigilance, ensuring the safe and effective use of medicines.
By systematically identifying, evaluating, and addressing drug-related risks, ADR monitoring protects public health and enhances patient outcomes.
The success of ADR programs depends on active participation from healthcare professionals, patients, and regulatory authorities, alongside the integration of advanced technologies for data collection and analysis.

In conclusion, ADR monitoring and reporting are vital to fostering trust in healthcare systems, improving the therapeutic landscape, and safeguarding public health.
A collaborative, proactive approach to ADR vigilance will continue to enhance drug safety and promote global health standards.

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

Result

The result of clinical research can refer to the outcomes of a clinical trial or study designed to evaluate the safety, efficacy, or impact of a medical treatment, drug, procedure, or device. The specific results depend on the type of research being conducted,

Adverse Drug Reaction (ADR) monitoring typically involve assessing and reporting on the safety profile of a drug or treatment based on the identification, evaluation, and documentation of any negative or unintended effects that patients experience after taking a medication. ADR monitoring is crucial in clinical research and post-marketing surveillance to ensure that drugs are used safely and effectively.

The result of Adverse Drug Reaction (ADR) reporting typically involves several outcomes, depending on the process and objectives. Below are some key aspects of ADR reporting results:

Efficacy: This refers to whether the treatment or intervention being studied works as intended. It might be measured in terms of improved health outcomes, reduced disease symptoms, or cure rates.

Safety: Clinical research also assesses the safety of treatments, looking for potential adverse effects, side effects, or long-term risks. Safety data often include the frequency and severity of any negative reactions observed in participants.

Statistical Significance: Research results are often presented in terms of statistical significance. This shows whether the results observed are likely due to the treatment rather than chance. A p-value of less than 0.05 is often used to indicate significance.

Comparative Effectiveness: Some clinical trials compare new treatments to existing ones or to a placebo, helping to understand how effective a new drug or therapy is in relation to current options.

Quality of Life: Some studies measure how a treatment affects patients' quality of life, including their physical, emotional, and social well-being.

Patient-Reported Outcomes: These are measures of health outcomes based on reports from patients themselves, such as symptom improvement or the experience of side effects.

REFERENCE

1. *Clinical trial designs. Nair B. Indian Dermatol Online J. 2019;10:193–201. doi: 10.4103/idoj.IDOJ_475_18. [DOI] [PMC free article] [PubMed] [Google Scholar]*
2. *Alcohol, Drug Abuse, and Mental Health Administration. 1991. ADAMHA Extramural Activities. ADAMHA Program Analysis Report No. 91-23. Rockville, Maryland.*
3. *American Federation for Clinical Research. 1992. Draft recommendations on policy issues to be considered in the NIH strategic plan. Clin. Res. 40:189-196. [PubMed]*
4. *Ameis SH, Kassee C, Corbett-Dick P, Cole L, Dadhwal S, Lai M-C, VeenstraVanderWeele J, Correll CU. Systematic review and guide to management ofcore and psychiatric symptoms in youth with autism. Acta Psychiatr Scand.2018;138(5):379*
5. *Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate- specific antigen as a serum marker for adenocarci-noma of the prostate. N Engl J Med. 1987;317(15):909- 916.*
6. *Hernandez J, Thompson IM. Prostate- specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894- 904.*
7. *Martin RM, Donovan JL, Turner EL, et al. Effect of a low- intensity PSA- based screening intervention on prostate can-cer mortality: the CAP randomized clinical trial. JAMA. 2018;319(9):883- 895*
8. *Aeries N. Consumer reporting of ADRs. WHO Drug Information. 1995;14:211–215. [Google Scholar]*
9. *Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M. What can we learn from parents about enhancing participation in Pharmacovigilance? British J Clin Pharmacol. 2012;78(2):312–322. doi: 10.1111/j.1365-2125.2012.04441.x. [DOI] [PMC free article] [PubMed] [Google Scholar]*
10. *Arora D. Pharmacovigilance obligations of the pharmaceutical companies in India. Indian J Pharmacol. 2008;40:13–16. [PMC free article] [PubMed] [Google Scholar]*
11. *Bahri P, Tsintis P. Pharmacovigilance–related topics at the level of the International Conference on Harmonisation (ICH) Pharmacoepidemiol Drug Saf. 2005;14:377–387. doi: 10.1002/pds.1043. [DOI] [PubMed] [Google Scholar]*
12. *Bates DW, Cullen DJ, Laird N. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274:29–34. doi: 10.1001/jama.1995.03530010043033. [DOI] [PubMed] [Google Scholar]*
13. *Beard K. Adverse reactions as a cause of hospital admission in the aged. Indian J*
14. *Pharmacol. 1992;2:356–357. doi: 10.2165/00002512-199202040-00008. [DOI] [PubMed] [Google Scholar]*
15. *Biswas P. Pharmacovigilance safety matters. Indian J Pharmacol. 2008;7613(40):1–3. [PMC free article] [PubMed] [Google Scholar]*

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 11 | November 2024 - Peer Reviewed Journal

16. *Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol. 2007;39:124–128. doi: 10.4103/0253-7613.33431. [DOI] [Google Scholar]*
17. *Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824–829. doi: 10.1001/jama.281.9.824. [DOI] [PubMed] [Google Scholar]*
18. *Carlo T, Francesco S. Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin. J Antimicrob Chemother. 1978;4:73–83. doi: 10.1093/jac/4.suppl_a.73. [DOI] [PubMed] [Google Scholar]*